Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects

Interference with ERK-dimerization at the nucleocytosolic interface targets pathological ERK1/2 signaling without cardiotoxic side-effects

Drugs targeting dysregulated ERK1/2 signaling can cause severe cardiac side effects, precluding their wide therapeutic application. Here, a new and cardio-safe targeting strategy is presented that interferes with ERK dimerization to prevent pathological ERK1/2 signaling in the heart and cancer.

Guardado en:
Detalles Bibliográficos
Autores principales: Angela Tomasovic, Theresa Brand, Constanze Schanbacher, Sofia Kramer, Martin W. Hümmert, Patricio Godoy, Wolfgang Schmidt-Heck, Peter Nordbeck, Jonas Ludwig, Susanne Homann, Armin Wiegering, Timur Shaykhutdinov, Christoph Kratz, Ruth Knüchel, Hans-Konrad Müller-Hermelink, Andreas Rosenwald, Norbert Frey, Jutta Eichler, Dobromir Dobrev, Ali El-Armouche, Jan G. Hengstler, Oliver J. Müller, Karsten Hinrichs, Friederike Cuello, Alma Zernecke, Kristina Lorenz
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/422072e270cd48449067eb1413f577cb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Drugs targeting dysregulated ERK1/2 signaling can cause severe cardiac side effects, precluding their wide therapeutic application. Here, a new and cardio-safe targeting strategy is presented that interferes with ERK dimerization to prevent pathological ERK1/2 signaling in the heart and cancer.

Ejemplares similares